BAB 5
SIMPULAN

5.1. Simpulan

- Pada pelepasan dan penetrasi, secara umum HPMC, propilen glikol dan interaksi antara keduanya memberikan efek yang positif meningkatkan penetrasi propranolol HCl.

  HPMC memberikan efek negatif menurunkan pelepasan propranolol HCl, propilen glikol memberikan efek positif meningkatkan pelepasan propranolol HCl dan interaksi antara HPMC dan propilen glikol memberikan efek negatif menurunkan pelepasan propranlol HCl.

  HPMC memberikan efek positif meningkatkan penetrasi propranolol HCl, propilen glikol memberikan efek positif meningkatkan penetrasi propranolol HCl dan interaksi antara HPMC dan propilen glikol memberikan efek positif meningkatkan penetrasi propranolol HCl.

- Berdasarkan kondisi uji optimal, komposisi yang optimum adalah HPMC 18,2% dan propilen glikol 40%. Secara teoritis, kondisi uji tersebut menghasilkan nilai pelepasan sebesar 7,48561 µg/ml dan nilai penetrasi sebesar 0,0900414 µg/ml.

5.2. Alur Penelitian Selanjutnya

- Penelitian lanjutan perlu dilakukan terhadap kondisi uji optimum yang diformulasikan dalam bentuk *patch*. Pengujian dilakukan dengan durasi waktu yang lebih panjang sehingga diperoleh fluks tunak.
- Penelitian lanjutan terhadap sediaan *patch* kondisi uji optimum terpilih dilakukan secara *in vivo* untuk mengetahui parameter farmakokinetika.

- Penelitian lanjutan perlu diuji pengaruh *enhancer* terhadap penetrasi agar bahan obat yang terpenetrasi lebih besar dan mencapai kadar dalam darah lebih tinggi dibandingkan dengan hanya menggunakan *plasticizer.*
- Penelitian lanjutan perlu diuji dengan menggunakan konsentrasi HPMC yang lebih rendah sehingga pelepasan dan penetrasinya lebih baik

DAFTAR PUSTAKA

Arellano, A., Santoyo, S., Martin, C., and Ygartua., 1999, Influence of Propylene Glycol and Isopropyl Myristate on the *In Vitro* Percutaneous Penetration of Diclofenac Sodium from Carbopol Gels, **International Journal of Pharmaceutics,** 7(2), 129 – 135.

Barry, B.W., 1991, Lipid Protein Partioning Theory of Skin Penetration Enhancement, **J. Control. Release.,** 15, 237 – 248.

Benson, H.A.E., 2005, **Transdermal Drug Delivery: Penetration Enhancement Techniques, Curr. Drug Delivery,** 2, 23 – 33.

Bolton, S., 1990, **Pharmaceutical Statistics, Practical and Clinical Application,** Marcel Dekker, New York, 309 – 319.

Bouwstra, J.A., Bergh, B.A.I., and Suhenon, M., 2000, Topical Application of Drug, in: **Drug Targeting Technology,** Schreier, H (ed), Marcel Dekker, New York, 247 – 249.

Chien, Y.W., 1992, **Transdermal Drug Delivery System in Novel Drug Delivery System,** Marcel Dekker, New York, 302 – 304.

Corbo, Michael., Liu, Jue-Chen., and Chien, Y.W., 1989, Bioavailability of Propranolol Following Oral and Transdermal Administration in Rabbits, Vol. 79, Issue 7, **Journal of Pharmaceutical Science,** 584 – 587.

Farmakope Indonesia. Edisi III, 1979. Jakarta, Departemen Kesehatan Republik Indonesia hal.15

Green, P.G., Shroot, B., Flanagan, M., and Guy, R.H., 1993, Iontophoretic Drug Delivery, in: **Pharmaceutical Skin Penetration Enhancement,** Hadgraff, J (ed), Marcel Dekker, New York, 311 – 314.

Guy, R., and Hadgraff, J., 1992, Percutaneous Penetration Enhancement: Phisicochemical Consideration and Implication for Prodrug Design, in: **Prodrugs, Topical and Ocular Drug Delivery,** Sloan, K.B (ed), Marcel Dekker, New York, 5 – 11

Katzung, B.G., 2001, **Farmakologi Dasar dan Klinik,** ed. 1, terjemahan Sjabana, D., Rahardjo., Sastrowardoyo, W., Hamzah., S.I, Endang., Uno, I., dan Purwaningsih, S., Penerbit Salemba Medika, Jakarta, 288 – 290.

Kibbe, A.H., 2000, **Handbook of Pharmaceutical Excipients,** 3rd ed., American Pharmaceutical Association, Washington DC, 252 – 255, 442 – 444.

Krishnaiah, S.Y., and Al-Saidan, S.M., 2008, **Transdermal Permeation of Trimetazidine from Nerodilol-Based HPMC Gel Drug Reservoir System across Rat Epidermis,** paper, Faculty of Pharmacy, Kuwait University, Kuwait, 37 – 42.

Kumar, R., and Philip, A., 2007, Modified Transdermal Technologies: Breaking the Barrier of Drug Permeation via the Skin, **Trop. J. Pharm. Res.,** 6(1), 633 – 644.

Lippold, B.C., 1984, **Biopharmacie, Eine, Einfuhrung zu den Wichtigsten Arznelformen,** Wissenschaft Verlagsge.mbH, Stuttgart WVG, 50.

L.K, Omray., S, Kohli., A.J, Khodape., S, Patil., A, Gajbhiye. and G.P, Agrawal., 2008, Development of Mesophasic Microreservoir-Based Transdermal Drug Delivery System of Propranolol, Vol. 7, Issue 5, **Indian Journal of Pharmaceutical Sciences.,** 7(5), 578 – 584.

Moolgaard, B., 1993, Synergistic Effect in Percutaneous Enhancement in Walters, **Pharmaceutical Skin Penetration Enhancement,** Hadgraft, J (ed), Marcel Dekker, New York, 229 – 239.

Pandit, Vinay., Khanum, Aisha., Bhaskaran, Shyamala., and Banu, Vasiha., 2009, Formulation and Evaluation of Transdermal Films for the Treatment of Overactive Bladder, **International Journal of PharmTech Research.,** 1(3), 799 – 804.

R.H, Patel., G.N, Patel., R.B, Patel., and M.M, Patel., 2009, Development of Dual Layers Drugs Delivery for Motion Sickness, **International Journal of PharmTech Research.,** 1(2), 173 – 178.

Scheindlin, Stanley, 2004, **Transdermal Drug Delivery: Past, Present, Future.,** Vol 4, Issue 6, 308 – 312.

Schunn, C.D., and Wallach, D., 2006, **Evaluating Goodness-of-Fit in Comparison of Models to Data,** Uniersity of Pittsburgh, Pittsburgh, 7 – 23.

Tiwari, S.B., and Rajabi – Siahboomi, A.R., 2009, Applictions of Complementary Polymers in HPMC Hydrophilic Extended Release Matrices, **The Science and Business of Drug Development in Specialty Pharma, Biotechnology, and Drug,** 9(7), 2 – 7.

Trommer, H., and Neubert, R.H.H., 2006, Overcoming the Stratum Corneum: the Modulation of Skin Penetration, **Skin Pharmacol Physiol,** 19, 106 – 121

.

Vecchia, B.E., and Bunge, A.L., 2006, Animal Model: A Comparison of Permeability Coefficient for Excised Skin from Human and Animals, in: **Dermal Absorption Model in Toxicology and Pharmacology,** Riviere, J.E (ed), Taylor and Francis, New York, 305 – 328.

Verma, P.R., Iyer, S.S., 2000, Controlled Transdermal Delivery of Propranolol Using HPMC Matrices: Design and *In-Vitro* and *In-Vivo* Evaluation, **J. Pharm Pharmacol,** 52(2), 151 – 156.

V.G, Jamakandi., J.S, Mulla., B.L, Vinay., and H.N, Shivakumar., 2009, Formulation, Characterization, and Evaluation of Matrix-Type Transdermal Patches of a Model QAntihypertensive Drug, Vol. 3, Issue 1, **Asian Journal of Pharmaceutics.,** 59 – 65.

Vogelpoel, H., Welink, J., Amidon, G.E., H.E., Midha., K.K., Olling, M., Shah. V.P., and Barends, D.M., 2004, Biowaiver Monographs for Immediate Release Solid Oral Dossage Forms Based on Biopharmaceutics Classification System (BSC) Literature Data: Verapamil Hydrochloride, Propranolol Hidrochloride, and Atenolol, **J. Pharm Sci.,** 93(8), 1945 – 1951.

Walker, R.B., and Smith, E.W., 1996, The Role of Percutaneous Penetration Enhancers, Vol. 18, **Adv. Dug Deliv. Rev.,** 295 – 301.

Williams, Adrian., 2003, **Transdermal and Topical Drug Delivery,** 1 st ed., Pharmaceutical Press, London, 1 – 84.

Winek, C.L., Wahba, W.W., and Balzer, T.W., 2001, **Winek's Drug and Chemical Blood-Level Data.,** 1 – 17.